Literature DB >> 10739328

Tardive dyskinesia in older patients.

D V Jeste1.   

Abstract

Neuroleptic-induced tardive dyskinesia, which often appears in middle-aged and older adults early in the course of treatment with low doses of conventional antipsychotics, is 5 to 6 times more prevalent in elderly than in younger patients. In addition to age, other risk factors for tardive dyskinesia include early extrapyramidal symptoms (EPS), cumulative amounts of neuroleptics, duration of neuroleptic treatment, and history of alcohol abuse and/or dependence. The atypical antipsychotics, which have a low liability for EPS, are likely to also have low potential for tardive dyskinesia, despite the paucity of controlled studies. Starting and maintenance doses of the atypical antipsychotics should generally be lower in older than in younger adults.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739328

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

Review 2.  New wine in old bottle: late-life psychosis.

Authors:  Alana Iglewicz; Thomas W Meeks; Dilip V Jeste
Journal:  Psychiatr Clin North Am       Date:  2011-06

3.  Tardive Dyskinesia: Spotlight on Current Approaches to Treatment.

Authors:  Sarah M Debrey; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

Review 4.  Movement disorders of the mouth: a review of the common phenomenologies.

Authors:  C M Ghadery; L V Kalia; B S Connolly
Journal:  J Neurol       Date:  2022-07-29       Impact factor: 6.682

5.  Atypical antipsychotics for older adults: are they safe and effective as we once thought?

Authors:  Dilip V Jeste; Jeanne E Maglione
Journal:  J Comp Eff Res       Date:  2013-07       Impact factor: 1.744

6.  A collaborative model for research on decisional capacity and informed consent in older patients with schizophrenia: bioethics unit of a geriatric psychiatry intervention research center.

Authors:  Dilip V Jeste; Laura B Dunn; Barton W Palmer; Elyn Saks; Maureen Halpain; Alison Cook; Paul Appelbaum; Lawrence Schneiderman
Journal:  Psychopharmacology (Berl)       Date:  2003-05-27       Impact factor: 4.530

7.  Concomitant use of two or more antipsychotic drugs is common in Sweden.

Authors:  Annica Bergendal; Helena Schiöler; Björn Wettermark; Karin Sparring Björkstén
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

8.  A Perspective on the Primary Care of Patients With Behavior, Mood, and Thought Disturbances: Clinical Applications of Olanzapine.

Authors:  Donald P. Hay; Daniel J. Hurley; Hillary C. McGuire; Linda K. Hay
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-10

Review 9.  ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.

Authors:  Dilip V Jeste; Dan Blazer; Daniel Casey; Thomas Meeks; Carl Salzman; Lon Schneider; Pierre Tariot; Kristine Yaffe
Journal:  Neuropsychopharmacology       Date:  2007-07-18       Impact factor: 7.853

10.  No association between PAWR gene polymorphisms and tardive dyskinesia in schizophrenia patients.

Authors:  Il-Soo Kim; Ho-Kyoung Yoon; Seung-Gul Kang; Young-Min Park; Yong-Ku Kim; Seung-Hyun Kim; Jung-Eun Choi; Leen Kim; Heon-Jeong Lee
Journal:  Psychiatry Investig       Date:  2012-05-22       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.